Nitin Jain, MD | Authors

Articles

Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALL

January 07, 2022

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

December 06, 2016

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.

New Checkpoint Inhibitors Under Investigation in CLL

September 29, 2016

Nitin Jain, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, discusses the checkpoint inhibitors under investigation in chronic lymphocytic leukemia (CLL).